Evidence map›Paper›PMID 29764948›Full record

ArticlemBio2018

Inducible Lung Epithelial Resistance Requires Multisource Reactive Oxygen Species Generation To Protect against Viral Infections.

Carson T Kirkpatrick, Yongxing Wang, Miguel M Leiva Juarez, Pooja Shivshankar, Jezreel Pantaleón García, Alexandria K Plumer, Vikram V Kulkarni, Hayden H Ware, Fahad Gulraiz, Miguel A Chavez Cavasos and 11 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Epithelial STAT3: A New Twist in Inducible Antimicrobial Resistance.American journal of respiratory cell and molecular biology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Response of Lung Microbiota to Changes of Pulmonary Innate Immunity under Healthy Conditions.American journal of respiratory and critical care medicine · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Carson T Kirkpatrick *Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yongxing Wang *Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Miguel M Leiva JuarezDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pooja ShivshankarDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jezreel Pantaleón GarcíaTecnológico de Monterrey School of Medicine, Monterrey, Mexico.
Alexandria K PlumerThe University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA.
Vikram V KulkarniDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hayden H WareDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fahad GulraizDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Miguel A Chavez CavasosDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gabriela Martinez ZayasTecnológico de Monterrey School of Medicine, Monterrey, Mexico.
Shradha WaliThe University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA.
Andrew P RiceDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Hongbing LiuDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
James M TourSmalley Institute for Nanoscale Science and Technology, Rice University, Houston, Texas, USA.
William K A SikkemaSmalley Institute for Nanoscale Science and Technology, Rice University, Houston, Texas, USA.
Ana S Cruz SolbesMichael E. Debakey Heart and Vascular Institute, Houston Methodist Hospital, Houston, Texas, USA.
Keith A YoukerMichael E. Debakey Heart and Vascular Institute, Houston Methodist Hospital, Houston, Texas, USA.
Michael J TuvimDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Burton F DickeyDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Scott E EvansDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA seevans@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USHouston Methodist · USRice University · USTecnológico de Monterrey · MX

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Inducible epithelial antiviral resistance to prevent asthmaDP2HL123229 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2013 to 2013
$2.4M
Epithelial mechanisms of inducible resistance to AML-associated pneumoniaR01HL117976 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2014 to 2018
$2.0M
NCI NIH HHS P30 CA016672NHLBI NIH HHS DP2 HL123229NHLBI NIH HHS R01 HL117976
6 · The paper itself

Abstract

Viral pneumonias cause profound worldwide morbidity, necessitating novel strategies to prevent and treat these potentially lethal infections. Stimulation of intrinsic lung defenses via inhalation of synergistically acting Toll-like receptor (TLR) agonists protects mice broadly against pneumonia, including otherwise-lethal viral infections, providing a potential opportunity to mitigate infectious threats. As intact lung epithelial TLR signaling is required for the inducible resistance and as these cells are the principal targets of many respiratory viruses, the capacity of lung epithelial cells to be therapeutically manipulated to function as autonomous antiviral effectors was investigated. Our work revealed that mouse and human lung epithelial cells could be stimulated to generate robust antiviral responses that both reduce viral burden and enhance survival of isolated cells and intact animals. The antiviral protection required concurrent induction of epithelial reactive oxygen species (ROS) from both mitochondrial and dual oxidase sources, although neither type I interferon enrichment nor type I interferon signaling was required for the inducible protection. Taken together, these findings establish the sufficiency of lung epithelial cells to generate therapeutically inducible antiviral responses, reveal novel antiviral roles for ROS, provide mechanistic insights into inducible resistance, and may provide an opportunity to protect patients from viral pneumonia during periods of peak vulnerability.

Indexed as

AnimalsEpithelial CellsFemaleHumansInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInterferon Type ILungMaleMiceMice, Inbred C57BLReactive Oxygen SpeciesToll-Like ReceptorsInterferon Type IReactive Oxygen SpeciesToll-Like Receptorsinducible resistancelung epitheliummucosal immunityreactive oxygen speciesToll-like receptorsviral pneumonia

Identifiers

PMID29764948
PMCPMC5954225
OpenAlexW2804581180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.